The same authors, in a subsequent paper, demonstrated that treatment with secoiridoid derivatives, such as ligstroside aglycone, deacetoxyoleuropein aglycone, and oleuropein glycoside in overexpressing HER2 breast cancer cells, was more significantly effective in its anti-cancer effect by suppressing fatty acid synthase (FASN), when compared to trastuzumab treatment [130]. This evidence concerns the gene ERBB2 and breast cancer.